{
    "name": "imipenem/cilastatin",
    "comment": "Rx",
    "other_names": [
        "Primaxin"
    ],
    "classes": [
        "Carbapenems"
    ],
    "source": "https://reference.medscape.com/drug/primaxin-imipenem-cilastatin-342562",
    "pregnancy": {
        "common": [
            "Available data from a small number of postmarketing cases in pregnancy are not sufficient to identify any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Developmental toxicity studies with imipenem and cilastatin sodium (alone or in combination) administered to mice, rats, rabbits, and monkeys at doses 0.4 to 2.9 times the recommended human dose (RHD), (based on body surface area), showed no drug-induced fetal malformations",
                    "Embryofetal development studies with imipenem/cilastatin administered to cynomolgus monkeys at doses similar to RHD (based on body surface area) showed an increase in embryonic loss"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are insufficient data on presence of imipenem/cilastatin in human milk, and no data on effects on breastfed child, or on milk production; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to imipenem or cilastatin"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "History of hypersensitivity to penicillins",
                "Use with caution in CNS disorders (eg., history of seizures); adjust dosage in renal impairment to avoid risk of seizures; carbapenem use has been associated with seizures",
                "Prolonged use increases risk of superinfections",
                "Use with caution in renal impairment; adjust dosage in moderate to severe renal dysfunction",
                "Carbapenem use may decrease serum levels of divalproex sodium or valproic acid",
                "Combination with aminoglycosides may thwart resistant P aeruginosa",
                "Not for use in children with CNS problems",
                "Clostridioides difficile associated diarrhea (CDAD) reported and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "BCG intravesical live",
            "description": {
                "common": "imipenem/cilastatin decreases effects of BCG intravesical live by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Intravesical BCG prescribing information states that antimicrobial therapy for other infections may interfere with the effectiveness of BCG intravesical. Antibiotics with activity against mycobacteria are of the greatest concern; however, avoiding all antimicrobial therapy during treatment is currently recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "imipenem/cilastatin decreases effects of cholera vaccine by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "divalproex sodium",
            "description": {
                "common": "imipenem/cilastatin will decrease the level or effect of divalproex sodium by  unknown mechanism. Avoid or Use Alternate Drug. Data from in vitro and animal studies suggest carbapenems may inhibit hydrolysis of the valproic acid glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid/divalproex sodium."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ganciclovir",
            "description": {
                "common": "ganciclovir, imipenem/cilastatin. unknown mechanism. Avoid or Use Alternate Drug. Coadministration may increase risk of seizures. Avoid unless potential benefit outweighs the risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "microbiota oral",
            "description": {
                "common": "imipenem/cilastatin decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "probenecid",
            "description": {
                "common": "probenecid increases levels of imipenem/cilastatin by decreasing renal clearance. Avoid or Use Alternate Drug. Coadministration increases the plasma level and half-life of imipenem."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "valacyclovir",
            "description": {
                "common": "valacyclovir, imipenem/cilastatin. unknown mechanism. Avoid or Use Alternate Drug. Coadministration may increase risk of seizures. Avoid unless potential benefit outweighs the risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "valproic acid",
            "description": {
                "common": "imipenem/cilastatin will decrease the level or effect of valproic acid by  unknown mechanism. Avoid or Use Alternate Drug. Data from in vitro and animal studies suggest carbapenems may inhibit hydrolysis of the valproic acid glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid/divalproex sodium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "imipenem/cilastatin decreases effects of BCG vaccine live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. BCG vaccine prescribing information states that antimicrobial or immunosuppressive agents may interfere with the development of the immune response and should be used only under medical supervision."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine, imipenem/cilastatin. Other (see comment). Use Caution/Monitor. \nComment: Cyclosporine may increase the neurotoxic effects of imipenem. Cases reports describe imipenem increasing or decreasing cyclosporine serum concentration levels."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate",
            "description": {
                "common": "imipenem/cilastatin decreases effects of sodium picosulfate by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate/magnesium oxide/anhydrous citric acid",
            "description": {
                "common": "imipenem/cilastatin decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "imipenem/cilastatin decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Postpone administering vaccine until at least 3 days after completing antibiotic regimen."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Phlebitis",
            "percent": "2-5"
        },
        {
            "name": "Eosinophilia",
            "percent": "4"
        },
        {
            "name": "Miscellaneous dermatologic effects",
            "percent": "3"
        },
        {
            "name": "Potentially false",
            "percent": "2"
        },
        {
            "name": "positive Coombs test",
            "percent": "2"
        },
        {
            "name": "Miscellaneous hematologic effects",
            "percent": "2"
        },
        {
            "name": "Transient increase in blood urea nitrogen",
            "percent": "1.5"
        },
        {
            "name": "BUN",
            "percent": "1-2"
        },
        {
            "name": "or serum creatinine",
            "percent": null
        },
        {
            "name": "Seizures",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "diarrhea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "Abnormal urinalysis",
            "percent": null
        },
        {
            "name": "Agitation",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "acute",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Dyskinesia",
            "percent": null
        },
        {
            "name": "Emergence of resistant strains of Pseudomonas aeruginosa",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Elevated liver function test",
            "percent": null
        },
        {
            "name": "LFT",
            "percent": null
        },
        {
            "name": "results",
            "percent": null
        },
        {
            "name": "Increased prothrombin time",
            "percent": null
        },
        {
            "name": "PT",
            "percent": null
        },
        {
            "name": "Neutropenia",
            "percent": null
        },
        {
            "name": "including agranulocytosis",
            "percent": null
        },
        {
            "name": "Palpitations",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Pseudomembranous colitis",
            "percent": null
        }
    ]
}